September 2025– date –

Oncology is the tip of the spear for China-origin innovation in global partnering. This article gives you a bird’s-eye view of the major deals, then goes deep into the operating logic behind ADCs, bispecific antibodies, checkpoint inhibi...

Even after successful primary treatment, disseminated cancer cells (DCCs) can persist in a dormant state for years and later “awaken,” leading to overt metastasis. Recent studies suggest that respiratory viral infections—such as influenz...

In Part 1, we reviewed mechanisms by which NK cells contribute to resistance against immune checkpoint blockade (ICB). In this follow-up article (Part 2), we discuss the clinical implications, potential strategies, and future directions ...

Natural killer (NK) cells have long been recognized as frontline effectors of tumor surveillance. However, recent studies reveal that their role within the tumor microenvironment (TME) is far more complex. NK cells are increasingly impli...

Introduction: Innovation Means Nothing Without Access GLP-1 obesity drugs have created explosive demand worldwide, but the critical bottleneck is cost. With prices reaching hundreds of dollars per month and long-term treatment required, ...

Claudin18.2 (CLDN18.2)-directed ADCs are rapidly emerging as a cornerstone in the treatment of advanced gastric and gastroesophageal junction (GEJ) cancers. Beyond SHR-A1904 and IBI343, several other candidates such as CMG901, EO-3021, a...

Introduction: Novo’s Layoff as a Symbol of Industry Transition In September 2025, Novo Nordisk announced a massive layoff of about 9,000 employees, roughly 12% of its global workforce. The decision comes amid intensified competition in t...

Two phase 1 trials—SHR-A1904 and IBI343—have propelled the clinical development of CLDN18.2-directed ADCs. This article provides a head-to-head comparison of their design, efficacy, safety, and positioning relative to zolbetuximab and ot...

In this article, we summarize the phase 1 trial of IBI343, reported in Nature Medicine (July 2025), focusing on its structural innovations, safety, efficacy, and position within the landscape of Claudin18.2-targeted ADCs. Drug Profile: M...

In a nutshell: Genome-wide CRISPR screens in patient-derived gastric cancer organoids uncovered strong dependencies on fatty-acid biosynthesis (ACC/ACACA) and cholesterol biosynthesis (LSS). Co-culture with enteric neurons (ENS) rewires ...

In Part 1 of our feature, we explored Enhertu’s groundbreaking pharmacological profile and its role in launching the second ADC boom. In this concluding part, we shift focus to intellectual property strategies, patent lifespans, and the ...

Antibody–drug conjugates (ADCs) targeting Claudin18.2 (CLDN18.2) have gained increasing attention as a novel therapeutic approach for advanced gastric and gastroesophageal junction (GEJ) cancers. Here, we summarize the phase 1 trial resu...

Antibody-drug conjugates (ADCs) have emerged as one of the most exciting modalities in oncology. Among them, HER2-targeted ADCs have undergone a dramatic transformation with the arrival of Daiichi Sankyo and AstraZeneca’s Enhertu, sparki...

In recent years, “exit” has become one of the most critical milestones for startups. In the biotech industry, traditional IPOs and M&As have been the main paths, but SPACs (Special Purpose Acquisition Companies) emerged as an alterna...

This series provides an in-depth review of the current landscape of Claudin18.2 (CLDN18.2)-targeted antibody–drug conjugates (ADCs) in gastric and gastroesophageal junction (GEJ) cancers. Structured into five parts, it covers pivotal cli...

Across pancreatic ductal adenocarcinoma (PDAC) models, tumor cells show marked intercellular heterogeneity in stress granules (SGs). A single-cell, cell-cycle–aware view reveals that SGs are maximally enriched in G2, powered by a lipid m...

Paper: A fluorescent-protein spin qubit (Nature, 4 Sep 2025) In a nutshell Enhanced yellow fluorescent protein (EYFP) is realized as an optically addressable spin qubit supporting initialization, readout, and coherent control. At liquid-...

Lead: Kidneys are prone to hypoxia, fueling AKI-to-CKD progression. A 2025 Science study shows that a hypoxia-induced “tRNA-Asp-GTC-3′tDR” safeguards kidney cells by maintaining autophagic flux through RNA autophagy. This adds a new laye...

In recent years, cancer and aging have increasingly been understood not as separate biological phenomena, but as interconnected processes. Immune decline and chronic inflammation in cancer patients may not be caused solely by treatment s...

Last updated: 2025-09-01 JST Lead: The shift from ex vivo to in vivo CAR-T is turning into a full-blown race. Big-ticket M&A, first-patient-dosed milestones, and multiple Phase-1 entries are consolidating the field into two lanes: le...